Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Aperture Therapeutics
Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
January 6, 2026
Aperture Therapeutics Announces Development Candidate Targeting CD33 to Restore Microglial Homeostasis in FTD and ALS
November 22, 2025